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Sinnukry Allelic imbalance or loss of heterozygosity (LOH) studies have been used extensively to identify
regions on chromosomes that may contain putative tumour-suppressor genes. We have undertaken an
extensive allelotype of 80 specimens of squamous cell carcinoma of the head and neck (SCCHN) using 145
polymorphic microsatellite markers on 39 chromosome arms. Allelic imbalances were found most frequently
on chromosome arms 3p, 9p, 17p and 18q with over 45% LOH and imbalances on lp, lq, 2p, Sq, 6p, 6q, 8p.
8q. 9q. lIq, 13q, 17q and 19q were found in more than 20% of SCCHN. These LOH data were analysed
against a range of cinicopathological parameters which included previously untreated and previously treated
tumours; correlations were found between LOH on 9q and nodes at pathology (P = 0.02) and between
histopathological grade and LOH on 12q (P = 0.02) and 13q (P = 0.01). In the group of previously untreated
tumours, a correlation was found between site of tumour and LOH on 3p (P = 0.019), and 8p (P = 0.029),
while TNM staging correlated with LOH on 3p (P = 0.019) and 17p (P = 0.016). Fractional allele loss (FAL)
was calculated for 52 tumours with LOH data on nine or more chromosomal arms and found to have a
median value of 0.22 (range 0.0-0.80). Correlations were found between FAL> median value and nodes at
pathology (P = 0.01) and tumour grade (P = 0.06), demonstrating that advanced tumours with lymph node
metastasis often had LOH at multiple sites. FAL>median value was found to correlate with a poor survival
(P<0.03) and, furthermore, FAL>median value correlated with poor survival in the previously untreated
patients (P<0.019). These results indicate that assessment of the accumulation of genetic damage. as provided
by allelotype data. provides a useful molecular indicator of the tumour behaviour and clinical outcome.
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The chromosomal locations of many different putative
human tumour-suppressor genes have been identified by loss
of heterozygosity (LOH) studies (Rees et al., 1989; Lasko et
al., 1991; Latif et al., 1992; Cunningham et al., 1993; Adam-
son et al., 1994). A number of oncogenic and tumour-
suppressor gene functions have been demonstrated in
squamous cell carcinoma of the head and neck (SCCHN)
(Field et al., 1989, 1991; Field, 1992), and the results of LOH
analysis currently point to several novel tumour-suppressor
gene sites in this disease (Maestro et al., 1993; Adamson et
al., 1994; Ah-See et al., 1994; Field et al., 1994; Kiaris et al.,
1994; Li et al., 1994; Loughran et al., 1994; Merlo et al.,
1994; Nawroz et al., 1994; van der Reit et al., 1994).
To date only two global analyses of the whole genome
have been undertaken with the view to determine the frac-
tional allele loss (FAL) of specific tumours and thus provide
information concerning the 'genetic burden' of the disease
during its progression as measured by clinicopathological
parameters and survival data. This type of analysis has been
undertaken in colorectal (Vogelstein et al., 1989) and bladder
cancers (Knowles et al., 1994), and provides an indication of
interacting genetic mechanisms in the development of these
diseases. In addition, the results of such detailed allelotypes
may aid the interpretation of carcinogenesis and the develop-
ment of molecular progression models for specific tumours.
We have undertaken a very comprehensive allelotype of
SCCHN using 145 microsatellite markers in order to identify
common regions of allelic imbalance and to analyse the
interactions of these regions by calculating the fractional
allele loss (FAL) in these tumours.
Materias and methods
Specimens
Eighty SCCHN tumour specimens were collected at the
Royal Liverpool University Hospital, Department of Oto-
rhinolaryngology and at the Walton Hospital Liverpool,
Maxillofacial Unit. Tumour samples obtained from surgical
specimens were frozen in liquid nitrogen and stored at
- 70C. The clinicopathological data on the 52 SCCHN used
in fractional allele loss analysis is given in Table I. This
group of patients had LOH information on nine or greater
(9-39) chromosome arms.
DNA extraction
All the tumour specimens used for LOH analysis were mic-
rodissected to yield at least 60% tumour cells before DNA
preparation. Genomic DNA was extracted from tumour
specimens using the Nucleon II DNA extraction kit (Scotlab)
following the manufacturer's instructions. Genomic DNA
samples were stored at 4°C.
PCR and LOH analtvsis
Microsatellite repeat primers were obtained from Isogen (The
Netherlands). PCR reactions were performed in a 25 pl reac-
tion volume and contained 200 ng of genomic DNA, 200 t.M
each dNTP, 5 pmol each of forward and reverse primers,
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Table I Clinicopathological characteristicsofthe52squamouscellcarinomasinvestigated onnine ormore
chromosomal arms
Survival
(months)
8
35
29
12
21
32
5
44
27
17
18
68
12
21
22
17
11
23
12
2
34
10
8
99
7
36
48
21
13
87
56
74
20
25
8
17
9
9
11
14
11
15
8
19
5
18
0
7
20
16
12
22
Fate
Died ofdisease
Alive
Alive
Died ofdisease
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Died of disease
Alive
Alive
Alive
Alive
Alive
Died of disease
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Died of disease
Died of disease
Died of disease
Alive
Alive
Alive
Alive
Alive
Died of disease
DOC
Died ofdisease
Alive
Died ofdisease
Alive
Alive
Died of disease
Alive
Died of disease
Alive
Died of disease
Alive
Alive
Died of disease
Alive
Died of disease
FAL'
S Median
0.00
0.00
0.00
0.05
0.07
0.10
0.10
0.11
0.11
0.11
0.11
0.13
0.13
0.14
0.15
0.15
0.15
0.17
0.17
0.19
0.20
0.20
0.20
0.21
0.21
> Median
0.22
0.22
0.22
0.23
0.23
0.24
0.28
0.30
0.30
0.31
0.33
0.33
0.33
0.33
0.35
0.35
0.35
0.36
0.38
0.41
0.44
0.45
0.46
0.47
0.50
0.56
0.80
PU, previously untreated; PT, previously treated; DOC, died ofother causes. 'FAL, fractional allele loss
(number ofchromosome arms lostdivided bythenumberofchromosome armsexamined). Medianvalueof
FAL in this group of SCCHN was 0.22.
0.5 units of Taq polymerase (Advanced Biotechnologies) and
2.5 ;LI 10 x buffer [670 mm Tns-HCI, pH 8.5; 166 mM ammo-
nium sulphate; 67 mM magnesium chloride; 1.7 mg ml-'
bovine serum albumin (BSA); 100ILM P-mercaptoethanol; 1%
(w/v) Triton X-100]. The reactions were denatured for 5 min
at 95'C then the DNA was amplified for 30 cycles of 95-C
for 30 s, 57C for 30 s and 72°C for 30 s. Aliquots of 10lAl of
the PCR product were electrophoresed for 10 h on a 10%
non-denaturing polyacrylamide gel at 250 V and visualised
by silver staining.
LOH or allelic imbalance was scored by direct visual com-
parison of the allelic ratios of the normal and tumour speci-
mens. Examples of heterozygous, homozygous and LOH in
tumour/normal SCCHN specimens are given in Figure 1.
Complete loss or reduced intensity of one allele in the
tumour was considered as LOH. In the cases where there was
only a reduced intensity of one allele this was considered to
be due to contamination of tumour tissue by normal stroma.
It has been previously noted by Ah-See et al. (1994) that the
PCR techniques used by a number of authors in similar
studies cannot readily distinguish between allelic duplication
or low-level amplification leading to loss of heterozygosity.
This caveat has to be taken into consideration when inter-
preting these results and thus LOH may not necessarily be
indicative of the presence of a tumour-suppressor gene.
Statistical analysis
Quantitative data were analysed by x2 or Fisher's exact test
where appropriate. Survival curves were drawn using the
Kaplan-Meier (1958) product limit estimate. Differences
between survival times were analysed by the log-rank method
(Peto et al., 1976).
Patient
number
0128
0041
1052
0353
1091
0302
0310
0223
0325
1086
0342
0339
0359
0204
1087
1101
0350
1075
0358
0336
0318
0340
0361
0315
1062
0215
0347
1164
0305
0225
0228
0202
0224
0327
0313
0346
0360
1084
0352
0192
0351
0348
0314
0343
0218
0335
0341
0329
0338
0184
0324
0078
Histor'
PT
PU
PU
PU
PU
PU
PT
PT
PU
PU
PU
PT
PT
PU
PU
PU
PT
PU
PU
PU
PT
PT
PU
PU
PU
PU
PT
PT
PU
PT
PT
PT
PU
PU
PU
PU
PU
PU
PU
PU
PU
PT
PU
PU
PU
PT
PU
PU
PU
PU
PU
PT
TNM
TI
TI
TIV
TIV
mll
Till
TIV
Ti
TV
TIV
Till
Ti
Till
Till
TV
TI
Till
TIl
TIV
Till
Till
Till
TI
TIV
Ti
TI
Till
TIV
TIV
Till
TIV
TiIl
TIV
TIV
TiV
TIV
Til
TIV
TIV
TIV
Till
TIV
TiV
TIV
Ti
Till
TiV
TIV
Till
TiV
Till
Histology
Moderate
Well
Moderate
Moderate
Well
Moderate
Moderate
Poor
Moderate
Poor
Moderate
Moderate
Moderate
Moderate
Moderate
Well
Moderate
Moderate
Moderate
Well
Moderate
Moderate
Moderate
Moderate
Moderate
Well
Moderate
Poor
Moderate
Moderate
Poor
Moderate
Moderate
Moderate
Moderate
Moderate
Moderate
Well
Moderate
Poor
Moderate
Not defined
Moderate
Moderate
Poor
Moderate
Moderate
Moderate
Moderate
Poor
Moderate
Poor
Nodes at
pathology
-ve
-ve
-ve
-ve
-ve
-ve
-ve
-ve
+ve
+ve
+ve
-ve
-ve
-ve
-ve
-ve
+ve
-ve
+ve
-ve
-ve
-ve
+ve
+ve
No data
-ve
-ve
-ve
+ve
-ve
No data
+ve
+ve
+ve
+ve
+ve
+ve
-ve
+ve
+ve
-ve
+ve
+ve
+ve
+ve
+ve
+ve
+ve
-ve
+ve
+ve
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Figure 1 Representative figure of allelic imbalance (loss of
heterozygosity). (a) Retention of heterozygosity. (b) Homo-
zygosity. (c) Allelic imbalance (loss of heterozygosity), loss of the
upper band in the tumour specimen. N, normal; T, tumour
DNA. 'Stutter' or 'shadow bands' may be seen in both the
normal and tumour lanes.
Results
A total of 80 SCCHN tumours were investigated for LOH,
using 145 microsatellite markers and loss on individual
chromosome arms was calculated using the total data set
(Table IL). A total of 1092 chromosomal arms were analysed,
of which 956 (88%) were informative. The most frequent
losses were found on chromosome arms 3p, 9p, 17p and 18q.
with over 450/o LOH; losses on lp, lq, 2p, 5q, 6p, 6q, 8p, 8q,
9q, llq, 13q, 17q and 19q were found in more than 20% of
cancers (Figure 2).
Loss ofheterozygosity at specific loci
The highest incidence of LOH was found on chromosome 9p
(24/39) with a 62% loss and this allelic imbalance was
especially concentrated between the D9S161 (9p21) and
D9S156 (9p23-9p22) informative markers in this region (JK
Field et al., in preparation), which agrees with the observa-
tions of van der Riet et al. (1994).
The second highest percentage of allelic imbalance (52%)
was found on chromosome arm 3p from 61 informative
tumours. Using 18 markers we found the greatest loss in the
3p24-p25 and 3pl3 regions and a very small incidence of
LOH at the 3p2l site, including the D3SJ217 marker (3p2l)
which had a LOH of only 10% (Field et al.. 1994; JK Field
et al., unpublished).
Chromosome 17p revealed an LOH of 50% with the
highest loss at the CHRNBI locus (17pl2-pll.l). Further-
more, as previously reported by Adamson et al. (1994), LOH
at this locus was found in 77% of the hypopharyngeal car-
cinomas studied.
Markers on 18q showed an overall LOH of 49% (20 41).
however the main area of loss was not associated with the
DCC marker at 18q21.1 but was found at D18S35
(18q21.l-q21.3) (33%) (Rowley et al., 1995).
Significant losses, 29% (13 45). were also found on
chromosome arm 5q. eight markers were used, including
D5S346 (5q21 -q22) in the APC MCC region which showed
35% LOH (9 26). Six patients in this group of tumours
showed loss only in this region. which was bounded in each
case by informative heterozygous markers centromeric and
telomenrc of D5S346. thereby indicating that this region plays
an important role in some SCCHN.
LOH on 8p has been demonstrated in a range of tumours
with the 8p2l.3-pll.22 region being of most interest. Our
investigations using five microsatellite markers on 8p have
shown 35% (14 40) LOH, which appears to be concentrated
particularly at the D8S87 (8pl2) and ANKI (8p2l.1-pll.2)
loci (29% and 20% LOH respectively). However, when the
results of these two markers were combined. 37% (13 35)
LOH was demonstrated (Kiaris et al., 1994).
LOH has also been observed on chromosome arm lp in a
range of tumours. with the lp3l.2-p21.3 region indicating
that this may be a further target region in SCCHN. The
cumulative loss of two markers in this region, DIS.159
(lp22.1-p21) and DIS167 (lp22-p21). was 24% (14,46).
Chromosome 11 contains an amplicon region at 11q13
which includes the int-2. cvclin D and EMS-I genes. We have
found 23% LOH (9 39) on the 1llq arm and LOH at the
int-2 locus was 17% (3 18).
In this data set, whole chromosome loss was seen only on
chromosome 17 and in four tumours: 78. 192, 225 and 335
(11% of cases). All of these chromosome arms showing LOH
at greater than 20% (3p. 17p. 9p, 18q, Sq, 8p, lp and 1 Icq)
have been previously shown to contain either known or
putative tumour-suppressor genes. However, there are other
arms in this study with greater than 20% LOH (lq, 2p, 6p,
6q, 8q. 13q. 17q and 19q) and these may also be target
regions involved in the development of SCCHN.
LOH data analvsed against a range ofclinicopathological
parameters
LOH data for each chromosomal arm were analysed against
a range of clinicopathological parameters, including site of
the tumour, histology, TNM staging, nodes at pathology and
survival (Table I). These calculations were undertaken on the
whole data set of 80 tumours (previously untreated and
previously treated) and on the two subgroups separately. In
the whole data set (80 SCCHN), correlations were found
between nodes at pathology and LOH on 9q (P = 0.020) and
between histopathological grading and LOH on 12q
(P = 0.022) and on 13q (P = 0.012). In the group of
previously untreated tumours, a correlation was found
between site and LOH on 3p (P = 0.032) and 8p (P= 0.029),
while TNM staging correlated with LOH on 3p (P = 0.019)
and 17p (P = 0.016). Only one association was found in the
group of previously treated patients, between nodes at
pathology and LOH on lIp (P = 0.045) (Table III).
Fractional allele loss
LOH data from all 39 chromosome arms were assessed
separately for the 52 SCCHN tumours which had inform-Hirnid o -e - ddip
XK F,eld et at
Table n Loss ofbeterozygosity analysis of 145 microsatellite markers in SCCHN on 39 chromosomal arms
Alele lossl Percentage
Chromosome informative LOH on
arm 5
Ip DIS171
DIS186
DIS162
DIS159
DIS167
AMY2B
Iq DIS187
DIS176
CRP
DISJ04
DIS179
ACTN2
2p TP
D2S207
D2S162
D2S126
MHC/CD8A
2q ILIA
D2S103
D2S104
3p D3S1435
D3587
D3S1038
D3S1304
D3S656
D3S1252
D3S1293
THRB
D35266
D3S1235
D3S966
D3S1289
D3S1067
D3S1217
D3S1261
D3S1079
D3S659
D3S1284
3q D3S1269
RHO
4p D4S43
HOX7
GABRBI
4q D4S392
D4S194
D4S243
5p D5S11
Sq D5S118
D5S357
D5S507
D5S346
lL9
D5S210
D5S209
DSS211
6p D6S344
TRMI
D6S271
6q D6S286
D6S262
D6S281
7p D7S53I
7q D7S473
D7S550
8p D8S20I
D8S265
I v' ,%I6I
Localisation
lp36.3
lp35-p32
lp31-p22
lp22.3-p21
lp22-p21
lp2l
lql2
lql2-q21
1q21-q23
1q21.1 -q23
1q31-q42
lq42-q43
2p25-p24
2p25-p23
2p25-p22
2p22-pl2
2pl2
2q13
2q23-q33
2q33-q37
3pter-p24.2
3p26-p24
3p26.1-p25.2
3p25.1-p24.2
3p25.1
3p25-p24.2
3p25-p24.2
3p24
3p25-p24
3p21.3-p21.2
3p21.3-p21.2
3p21.2-p21.1
3p21.1-p14.3
3p2l
3pl4-pl2
3p13
3p13
3pl3-pl2
3q21
3q21.3-q24
4pl6.3
4pl6.3-pl6.1
4pl3-pl2
4ql2-ql3
4q25-q34
4q31-q32
5p14.1-pl3.1
5cen-ql1.2
5qll-ql3.3
Sql1.2-ql3.3
5q21-q22
5q22.3-q3l.3
5q31.3-q33.3
5q31.3-q33.3
5q33.3-qter
6p24
6p23-ql2
6p21.2-p21.1
6ql6.3-q21
6q22.3-q23.1
6q27
7p
7q
7q31-qter
8pnte-p22
8p23-pilI
%@n -vx\
%@'l
%@Iv\\\\I
cases ea
10/37
5/18
7/31
2/16
32/61
4/32
1/13
2/15
2/12
13/45
3/14
6/24
1/13
1/14
14/40
Alele lossl Percentage
Chromosome informative LOH on
wch arm arm LLocs
27 8q D8S166
D8S164
D8S88
D8S85
D8S198
MYC
28 9p D9S54
D9S199
D9S156
D9S157
D9S162
IFNA
23 D9S171
D9S161
D9S200
D9S104
D9S50
13 9q D9S5S D9S103
D9S67
52 lOp D10S249
lOq D1OS09
D10S212
llp HRMS
TH
D11S875
D)1S419
lIq INT2
DRD2
D11S439
D11S874
12p D12S94
12q D12S43
D12S63
13q D13SJ51
D13S175
13 D13S168
D13565
8 D13S155 D13571
14q TCRD
13 D14S47
D]4S5J
15q GABRB3
17 CYPI9
D15587
29
16p HBAPI
16q D16S303
17p D17S578
TP53
D17S520
D17S799
CHRNBI
21 D17522
17q TCF2
GP3A
25 MPO
D17S551
18p D18S59
8 D18S52
7 D18S40
Localasto
8q1l.23-ql2
8ql3-q22.1
8q22.1-q22.3
8q23-qter
8q23.1-qter
8q24.12-q24
9pter-p22
9p23
9p23.3-p22
9p23-p22
9p23-p22
9p21
9p21
9p21
9p21-pl2
9p21
9p2l -pter
9q22.3-q33
9q33-qter
9q34-qter
lop
IOql1.2-qter
10qter
llpl5.5
lIp15.5
1 lpl5.4-pl3
1 lpl5.4-pl3
I 1q13.3
Ilq23.1
IIq23.3
1 Iq24-qter
12pter-pl3.2
12ql2-q24.1
12q22-q24.33
13qll-ql2.1
13qll-ql3
13ql1 -q22
13q
13q
13q32
14q11.2
14ql1.2-q22
14q32.1-q32
15ql1.2-ql2
15q21.1
15q32.1 -qter
16p13.3
16q24.3
17pl3.3-pl 1.2
17pl3.3
17pl3-pl2
l7pl3.1-p12
17pl2-pl 1.1
17pl2-pl 1.2
17ql1.2-ql2
17q21.32
17q21.3-q23
17q23-q25
18pter-pl 1.22
18pter-pl 1.22
18pl1.21
1183
cases each arm
7/33 21
24/39
6/30
1/11
2/16
5/39
9/39
1/7
2/13
8/30
2/19
2/17
2/15
0/17
18/36
12/40
5/31
62
20
9
13
13
23
14
15
27
11
12
13
0
50
30
16
35
PoHMd and caoew -
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Table II-coatimwd
Allele lossl Percentage
Chromosome informative LOH on
arm Locus Locahisation cases each arm
18q D18S34 18ql2.2-ql2.3 20!41 49
D18S35 18q21.1 -q21.3
DCC 18q21.1
D18S38 18q21.31
D18S42 18q22.1
D18S43 18q22.3 -q23
MBP 18q23
D18S70 18q23 -qter
l9p D19S20 l9pl3.3 0Z9 0
19q D19S49 19ql2-ql3.1 5 17 29
D19SJ80 19q13.4
20p D20S57 20pl3 0 14 0
20q D20S120 20q 1 11 9
21q D215156 21q22.3 1'12 8
22q IL2RB 22ql1.2-q12 0 15 0
ation on nine or greater (range 9-39) chromosome arms.
This subgroup of 52 tumours was composed of 36 previously
untreated tumours and 16 previously treated tumours.
Allelotypes derived from 145 microsatellite markers are pres-
ented diagrammatically in Figure 3. The fractional allele loss
(FAL) in a tumour is defined as the number of chromosomal
arms on which allelic imbalance was observed divided by the
number of chromosomal arms for which markers were infor-
mative in the patient's normal cells (Vogelstein et al., 1989).
The FAL values for this group of 52 SCCHN showed a
median value of 0.22 and a mean of 0.25 (range 0.0-0.80).
FAL values were assessed against the clinicopathological
data (tumour site, tumour grade, TNM staging, nodes at
pathology) by dividing the tumours into those with FAL>
median value and those with FAL <median value. A
positive correlation was found between FAL and nodes at
pathology (P = 0.01) and between FAL and tumour grade
(P = 0.06) (Table IV). This demonstrates that advanced
tumours with lymph nodal metastasis often had LOH at
multiple sites. No correlation was found between FAL and
the patient's history of smoking or drinking (Table V).
The FAL data was also investigated for a possible associa-
tion with clinical outcome using the log-rank analysis. It was
found that a FAL >median value correlated with poor sur-
vival (P<0.032), and furthermore that a FAL>median
value also correlated with a poor survival in the previously
untreated patients (P<0.019) when analysed separately. In
order to analyse a homogeneous group of patients for FAL
with clinical outcome, we calculated the log rank on the
subset of 40 advanced tumours (TNM III and IV) and this
also demonstrated a correlation between FAL and prognosis
(P<0.05).
D6cuson
In this detailed allelotype of SCCHN we have demonstrated
a complex set of genetic alterations, a finding that has also
been described in a range of human cancers (Vogelstein et
al., 1989; Sato et al., 1990, 1991; Fujimori et al., 1991;
Monrta et al., 1991; Tsuchiya et al., 1992; Yamaguchi et al.,
1992; Aoki et al., 1994; Fujino et al., 1994; Knowles et al.,
1994). The highest LOH was found on the chromosome arms
3p, 9p, 17p and 18q which is in general agreement with
previous studies on SCCHN (Ah-See et al., 1994; Nawroz et
al., 1994). Table VI provides an overview of the results
Table m LOH data analysed against a range of clinicopathological parameters
Chromosome
arm Site Nodes TNM Pathology
Total data
(n = 80) 9q NS 0.020 NS NS
previously 12q NS NS NS 0.022
treated/untreated 13q NS NS NS 0.012
Previously 3p 0.032 NS 0.019 NS
untreated 8p 0.029 NS NS NS
Previously 17p NS NS 0.016 NS
treated 1lp NS 0.045 NS NS
0
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Chromosome arms
Figwe 2 Frequency of allele loss on each chromosome arm in 80 squamous cell carcinomas of the head and neck. U, p arm; 0. q
arm.
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F_gwe 3 Individual allelotypes for 52 squamous cell carcinomas of the head and neck. These SCCHN tumours were investigated
on nine or more informative chromosomal arms (range 9-39). The FAL (fractional allele loss) data has been given for each
tumour specimen (range 0.0-0.80). *, LOH; 0, retention of heterozygosity; chromosome arms which were uninformative or not
done are not shown. Each square represents the summation of the LOH results on a single chromosome arm using all of the
informative markers, i.e. if there was allelic imbalance for any one of the markers tested for that specific chromosomal arm, then it
is indicated as a filled square.
undertaken in this study in comparison with those in the two
other allelotypes undertaken on SCCHN tumours. Both of
the previous studies used about one-third of the number of
markers used in this analysis: 58 markers (Nawroz et al.,
1994) and 52 markers (Ah-See et al., 1994) respectively.
Similar LOH values have been found at 3p, Sq, and 9q
between Ah-See et al. (1994) and these data (± 15%), in the
cases where the results may be compared. Also, similar LOH
findings may be seen between Nawroz et al. (1994) and this
data set for chromosome arms, Ip, Iq, 3p, 5q, 8p, 8q, 9p, 9q,
lIp, 17p, 17q and 19q (± 15%). fjowever, a number of
differences (> ± 20%) do exist between the previous reports
and our results on 9p, llq, 13q and 18q. The percentage
LOH for llq varies from 23%, 45% to 61% in the three
studies (Ah-See et al., 1994; Nawroz et al., 1994; these data
respectively), however the two previous studies only used two
markers on this chromosome arm. The data on 18q from
Nawroz et al. (1994) based on one marker give an LOH of
29%, whereas eight markers have been used in this study,
demonstrating an LOH of 49%. This analysis demonstrates
Table IV Association between FAL and nodes at pathology and
tumour grade
FAL
- Median >Median
Clinicalparameter value vahle P
Nodes at pathology
No nodes 17 8
Positive nodes 7 18 0.01
TNM status
TNM I and II 8 3
TNM III and IV 16 23 0.06
"Fisher's exact t-test.
that the results of the three allelotypes on SCCHN agree in
general, however when only a limited number of markers are
chosen per arm there is a very high probability that a target
region may be missed.
The results from this study provide further confirmation of
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Table V Association between FAL and a history of smoking and drinking in patients with SCCHN
Moderate Heavy Moderate Heavy
Non- smoker smoker Stopped Non- <21 units >21 units Stopped
smoker <20 per day >20 per day smoking Pa drinker per week per week drinking P'
FAL<,median 5 5 8 2 6 4 8 1
FAL>median 5 3 9 4 0.7 4 6 10 1 0.9
aFisher's exact t-test.
Table VI Comparison of LOH from three allelotypes of SCCHN
Ah-See et al. (1994) Nawroz et al. (1994) This study
Chromosome No. of No. of No. of
arm markers LOH (%) markers LOH (%) markers LOH (%)
lp 1 14a 2 30 6 27
lq 2 0a 1 23 6 28
3p 3 44 2 67 18 52
Sq 4 43 1 25 8 29
8p 1 10O 1 40 5 35
8q 1 7a 2 38 6 21
9p 1 24a 3 72 11 62
9q 2 35 2 18 3 20
1lp 1 5a 2 17 4 13
llq 2 45 2 61 4 23
13q 1 oa 2 54 6 27
17p 2 31 3 52 6 50
17q 1 9ga 2 31 4 30
18q 1 08 2 29 2 49
19q 1 08 2 40 2 29
aData taken from Figure 2, Ah-See et al. (1994).
target regions in SCCHN containing putative tumour-
suppressor genes on 3p and 9p as well as a high LOH
associated with the p53 gene. In addition, this analysis pro-
vides evidence for regions of minimal loss in SCCHN on lp,
8p, 17p and 18q (Adamson et al., 1994; Kiaris et al., 1994;
Rowley et al., 1995; K Taylor et al., in preparation). The lp
minimal area of loss has been located at lp3l.2-p2l.3, a
region previously shown by karyotype analysis to contain
cytogenetic abnormalities (Jin et al., 1990, 1993; Owens et al.,
1992). A minimal area of loss has also been identified on 8p
between 8pl2 and 8p21.2-pII in this series of tumours, a
region considered to contain a candidate tumour-suppressor
gene in colonic and hepatocellular carcinomas (Fujiwara et
al., 1993; Cunningham et al., 1994). We have recently des-
cribed a novel region on 17p distinct from TP53, at
CHRNBI (17q12-pl 1.1), in SCCHN which has a particular-
ly high loss in hypopharyngeal carcinomas (77%) (Adamson
et al., 1994). Furthermore the detailed analysis of 18q has
allowed us to identify a region at 18q21.1-q21.3 as a target
region in SCCHN, which does not appear to be the DCC
(deleted in colon cancer) gene as we found a very low LOH
at the DCC locus. Thus it may be argued that there is a
second tumour-suppressor gene in this region on 18q that is
involved in SCCHN.
Two further chromosomal regions considered to contain
tumour-suppressor genes in other neoplasms have not been
shown to play an important role in SCCHN. Even though
there is frequent LOH on 13q (Yoo et al., 1994) there does
not appear to be inactivation of the retinoblastoma gene, and
it has been argued by these authors that there may be
another tumour-suppressor locus at 13ql4. Also, the APC/
MCC locus on 5q, which has been demonstrated to be
involved in colorectal carcinomas (Kinzler et al., 1991) and
has previously been shown to have a high LOH in SCCHN
(Ah-See et al., 1994), may not in fact be the target locus, as
mutations in the APC gene have rarely been found in oral
cancers (Uzawa et al., 1994).
Analysis of LOH for each chromosomal arm was assessed
against a range of clinicopathological parameters (Table III).
In particular, a correlation was found between site and LOH
on 3p and 8p, while TNM staging correlated with LOH on
3p and 17p in previously untreated tumours. Also, in the
group of previously untreated and previously treated
tumours a correlation was found between LOH on 9q and
positive nodes at pathology, and histological grading cor-
related with LOH on 12q and 13q. In a detailed study
undertaken by Lee et al. (1994), on chromosome 13 (using 13
markers), a correlation was found between LOH on 13q and
lymph node metastasis. Moreover, these authors reported
that they found similar LOH in a subset of the tumours in
the adjacent non-malignant mucosa. However, no correlation
between LOH at 13q and lymph node metastasis was
observed in the study described here.
The phenomenon ofmicrosatellite instability (MI) (Mao et
al., 1994; Field et al., 1995) has been demonstrated in some
of these SCCHN tumours, but no correlation was found
between MI and LOH on any chromosome arm in this study.
MI is therefore considered to be a separate pathogenic
mechanism in the development of SCCHN.
The fractional allele loss (FAL) data were assessed for 52
tumours on which there was LOH information on nine or
more chromosome arms. In this group we found a median
FAL value of 0.22, mean of 0.25 (range 0.0-0.80). This
demonstrates that alleles were lost on average from 25% of
the chromosome arms in these tumours; a figure that is
comparable with that obtained in non-small-cell carcinoma
and colorectal carcinomas (0.2), bladder and breast car-
cinomas (0.11) and osteosarcarcinomas (0.32) (Sato et al.,
1990, 1991; Morita et al., 1991; Tsuchiya et al., 1992;
Knowles et al., 1994). The FAL values were compared with
the clinicopathological data based on FAL<median value
and FAL> median value. A correlation was found between
FAL and positive nodes at pathology (P = 0.01), a clinical
parameter considered to be the most useful prognostic
indicator in head and neck cancer. No statistical correlation
was found between FAL and site, TNM staging or his-
tological differentiation. A history of smoking and drinking
has been correlated with overexpression and mutations in the
p53 gene (Field et al., 1991, 1994; Field, 1992; Brennan et al.,
1995), but no correlation has been found between these
carcinogens and FAL in this analysis. In colorectal car-
cinomas, Vogelstein et al. (1989) found no correlation
between FAL and Dukes' classification or tumour size,
whereas in the allotype on bladder carcinomas, a correlationHied an cancer -
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was found between FAL and tumour grade but not with the
stage of the disease (Knowles et al., 1994). Thus, all three
analyses demonstrate no correlation between FAL and
tumour stage.
We have demonstrated that a FAL>median value cor-
related with a poor prognosis in all 52 patients analysed
(P<0.032) and also in the subset of previously untreated
patients (P<0.019) calculated by the log-rank method.
Vogelstein et al. (1989) also showed a relationship between
FAL and prognosis for colon cancers with a similar number
and distribution of patients (P<0.01) using Fisher's exact
test. Thus the argument originally proposed by Vogelstein et
al. (1989) that recognition of accumulated genetic damage, as
provided by the allelotype, provides a useful molecular
indicator of the tumour behaviour is supported by the
findings of this study.
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